dilluns, 27 de febrer del 2017

Viveve Medical reports success treating vaginal laxity

viveveViveve Medical recently published the results of a clinical study of its Viveve I treatment in the Journal of Sexual Medicine, showing that women who received the treatment reported being more likely to have no vaginal laxity.

The Viveve Treatment of the Vaginal Introitus to Evaluate Efficacy study is one of the first studies to study the safety and efficacy of energy-based procedures in gynecological applications that was randomized, single-blinded and sham-controlled. It was meant to show the efficacy and safety of Viveve treatment as opposed to a sham control procedure for vaginal introital laxity treatment. The study included two groups of women, one that was going to receive the treatment and the other that was going to be the sham group.

The Viveve I treatment uses cryogen-cooled monopolar radiofrequency (CMRF) to deliver gentle volumetric heating while cooling delicate surface tissue, allowing collagen to form. It is designed for women who are suffering from the changes in their bodies after giving birth. The treatment can be done in an outpatient clinic in a 30-minutes.

Get the full story on our sister site, Medical Design & Outsourcing.

The post Viveve Medical reports success treating vaginal laxity appeared first on MassDevice.



from MassDevice http://ift.tt/2mx7N9b

Cap comentari:

Publica un comentari a l'entrada